NCT02256878已完成1 期
A Study to Evaluate the Effect of a Single Oral Dose and Multiple Oral Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- AUC0-∞ of amitriptyline (area under the concentration-time curve of amitriptyline in plasma over the time interval from 0 extrapolated to infinity)
研究概览
简要总结
The objective of the study was evaluate that there is no clinically relevant interaction between amitriptyline (or its metabolite nortriptyline) and BIRT 2584 XX (or its metabolite BI 610100) when BIRT 2584 XX is administered as a tablet formulation to near steady state in an estimated high therapeutic dose. Pharmacokinetics (PK) of amitriptyline and nortriptyline were measured before dosing of BIRT 2584 XX, after the first dose of BIRT 2584 XX, and after repeated doses of BIRT 2584 XX near steady state
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female or male volunteers as determined by the results of screening based upon a complete medical history, including physical examination, measurement of vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead ECG, and clinical laboratory tests
- •Age ≥ 18 and ≤ 55 years
- •BMI ≥ 18.5 and ≤ 29.9 kg/m2 (body mass index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR, and ECG) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematologic, oncologic or hormonal disorders
- •Surgery of gastrointestinal tract (except appendectomy)
- •Diseases of the Central Nervous System (CNS) (such as epilepsy) or psychiatric disorders or neurological disorders
- •Relevant history of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24 h) within 1 month prior to administration of the study drug or during the trial
- •Use of any drugs which might influence the results of the trial within 10 days prior to study drug administration or expected during the trial
- •Participation in another trial with an investigational drug within 2 months prior to administration or expected during the trial
- •Smoker (>10 cigarettes or >3 cigars or >3 pipes/day); inability to abstain from smoking within 5 days before first drug administration until completion of the trial
- •Alcohol abuse (>60 g/day)
- •Drug abuse
- •Blood donation or loss >400 mL, within 1 month prior to study drug administration or expected during the trial
- •Clinically relevant laboratory abnormalities
- •For male subjects:
- •Male subjects whose sexual partners are currently not using an adequate method of contraception that would prospectively be maintained during the study, are to be excluded
- •Male subjects who are not willing to use condoms are to be excluded
- •For female subjects:
- •Pregnancy
- •Positive pregnancy test
- •No highly safe method of contraception in women of childbearing potential (in this context, only sterilization or male partner sterilization is considered a highly safe method of contraception). Hormonal contraceptives are not considered adequate due to possible drug interaction with BIRT 2584 XX
- •Lactation period
研究组 & 干预措施
BIRT 2584 XX + Amitriptyline
Experimental
BIRT 2584 XX:
Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)
Amitriptyline:
Single dose on day -8, day 1, and day 15
干预措施: BIRT 2584 XX (Drug)
BIRT 2584 XX + Amitriptyline
Experimental
BIRT 2584 XX:
Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)
Amitriptyline:
Single dose on day -8, day 1, and day 15
干预措施: Amitriptyline (Drug)
结局指标
主要结局
AUC0-∞ of amitriptyline (area under the concentration-time curve of amitriptyline in plasma over the time interval from 0 extrapolated to infinity)
时间窗: up to 15 days
AUC0-∞ ratio of amitriptyline/nortriptyline
时间窗: up to 15 days
次要结局
- Number of subjects with abnormal changes in laboratory parameters(up to 28 days)
- λz (terminal rate constant of the analytes in plasma)(up to 15 days)
- CL/F (apparent clearance of the analytes in the plasma after extravascular administration)(up to 15 days)
- Pre-dose levels of BIRT 2584 XX and BI 610100(up to 15 days)
- Cmax of nortriptyline (maximum concentration of nortriptyline in plasma)(up to 15 days)
- AUC0-∞ ratio of amitriptyline/nortriptyline(Day 1)
- MRTpo (mean residence time of the analytes in the body after po administration)(up to 15 days)
- AUC0-∞ of amitriptyline (area under the concentration-time curve of amitriptyline in plasma over the time interval from 0 extrapolated to infinity)(Day 1)
- Cmax of amitriptyline (maximum concentration of amitriptyline in plasma)(up to 15 days)
- AUC0-∞ of nortriptyline (area under the concentration-time curve of nortriptyline in plasma over the time interval from 0 extrapolated to infinity)(up to 15 days)
- AUC0-tz (area under the concentration-time curve of the analytes in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 15 days)
- tmax (time from dosing to the maximum concentration of the analytes in plasma)(up to 15 days)
- t1/2 (terminal half-life of the analytes in plasma)(up to 15 days)
- Assessment of tolerability by investigator on a 4-point scale(Day 28)
- Number of subjects with adverse events(up to 57 days)
- Vz/F (apparent volume of distribution during the terminal phase following an extravascular dose)(up to 15 days)
研究者
相似试验
尚未招募
不适用
To study the effect of application of gel in itching at vulval regioCTRI/2020/12/029527Dr D Y Patil College Of Ayurved And Research Centre
尚未招募
1 期
Study the effects of atibala churna in raktapradar (menorraghia)CTRI/2023/04/051404Dr Ravina kamdar
尚未招募
2 期
clinical trail on the effect of Aakshik (Terminalia bellirica) Sidhu on Hb percentage.CTRI/2024/03/064628Sane Guruji Arogya Kendra
招募中
2 期
A study held to see the effect of Yoga of Sound on mental health in working womeCTRI/2022/03/040778Shweta Kakade
招募中
2 期
A study to assess the effect of Yava Mantha as a pathya in the management of Prameha (Type 2 Diabetes mellitus).CTRI/2023/10/058187Sane Guruji Arogya Kendra